Nurix Therapeutics Reports Q3 2025 Revenue Decline to $7.9 Million, Increased Net Loss

Nurix Therapeutics, Inc. reported its financial results for the third quarter of 2025, revealing a total revenue of $7.9 million, a decrease from $12.6 million in the same period last year. The decline in revenue was primarily attributed to reduced collaboration revenue from its partnership with Sanofi, which concluded the initial research term for certain drug targets. However, revenue from the collaboration with Pfizer increased, partially offsetting the overall decline. For the nine months ended August 31, 2025, total revenue reached $70.4 million, significantly higher than $41.3 million for the same period in 2024, largely due to a $30 million license revenue recognized from Sanofi.

Operating expenses for the third quarter increased to $99.3 million, compared to $67.2 million in the prior year, driven by heightened research and development costs as the company accelerated clinical trials for its drug candidates, including bexobrutideg and zelebrudomide. The net loss for the quarter was $86.4 million, compared to a loss of $49.0 million in the same quarter of 2024. For the nine-month period, the net loss was $186.2 million, up from $135.0 million in the previous year, reflecting the company's ongoing investment in its clinical pipeline.

As of August 31, 2025, Nurix reported total assets of $522.5 million, a decrease from $669.3 million at the end of the previous fiscal year. The decline in assets was primarily due to a reduction in cash and cash equivalents, which fell to $78.4 million from $110.9 million. The company’s accumulated deficit also increased to $925.0 million, indicating the ongoing financial challenges faced as it continues to invest heavily in research and development.

Strategically, Nurix has been active in expanding its collaborations, including a recent agreement with Pfizer to develop targeted protein degraders. The company has received substantial upfront payments and is eligible for additional milestone payments totaling approximately $3.4 billion across its collaborations with Gilead, Sanofi, and Pfizer. As of the latest report, Nurix has $428.8 million in cash, cash equivalents, and marketable securities, which management believes will be sufficient to fund operations for at least the next 12 months.

Looking ahead, Nurix anticipates continued increases in research and development expenses as it advances its clinical trials and expands its drug candidate pipeline. The company remains focused on securing additional funding to support its long-term business objectives, which may include public or private equity offerings and collaborations. The management has expressed confidence in its ability to navigate the financial landscape, although it acknowledges the inherent risks and uncertainties associated with drug development and market conditions.